FDA commissioner stands firm on mifepristone access despite pressure from pro-life groups

04/29/2025 / By Laura Harris

FDA Commissioner Marty Makary reaffirmed that the FDA has no plans to restrict mifepristone, a key abortion medication, despite pressure from pro-life groups.
Mifepristone, approved in 2000 and used in over half of U.S. abortions, remains accessible via telemedicine in restrictive states, prompting conservative pushback.
A Supreme Court ruling in 2023 dismissed a lawsuit by conservative groups seeking stricter regulations, citing a lack of legal standing.
Makary stated the FDA would only reconsider policies if new safety data emerged, signaling no imminent restrictions.
Conservative backlash ensued, with figures like Daily Signal correspondent Elizabeth Mitchell criticizing Makary, claiming abortion pills endanger mothers and citing rising ER visits from complications.

Food and Drug Administration (FDA) Commissioner Marty Makary has insisted that the agency has no plans to reverse its recent expansion of access to mifepristone, a key abortion medication, despite ongoing pressure from pro-life groups.

Mifepristone, used with misoprostol to terminate pregnancies of up to 10 weeks, was first approved by the FDA in September 2000 and later approved a generic version in April 2019. Since then, it has accounted for over half of all U.S. abortions. Others have accessed it via telemedicine in states with abortion bans, prompting conservative lawmakers to push for stricter controls.

A coalition of doctors and conservative groups previously sued to reinstate strict rules, including banning telemedicine prescriptions. But the Supreme Court dismissed the case in 2023, ruling that plaintiffs lacked legal standing. (Related: Designed to KILL: Democrats demand that FDA cancel safety rules for abortion drug to make baby murder more accessible.)

In line with this, Makary stated that the FDA would only reconsider its policies if new data raised safety concerns during the Semafor World Economy Summit on April 24.

“There is an ongoing set of data that is coming into the FDA on mifepristone,” Makary said. “So if the data suggests something or tells us that there’s a real signal, we can’t promise we’re not going to act on that data.”

Makary adopted a more definitive stance during the summit than in his Senate confirmation hearing in March, where he promised only to review existing evidence on the drug without committing to any specific regulatory action. His latest comments suggest the FDA is unlikely to reverse course without significant new evidence.

Makary faces criticism from conservatives

Missouri Republican Sen. Josh Hawley slammed Makary over his remarks about mifepristone.

“This is exceptionally disappointing, to say the least. Not a good beginning at the FDA,” Hawley posted on his official account on X, formerly known as Twitter, along with a shared tweet from another X user about Makary and his statement during the summit.

Hawley supported advancing Makary’s nomination as the FDA commissioner even after the agency dismissed an attorney who had defended former President Joe Biden’s vaccine mandates and lax safety restrictions on mail-order abortion pills.

Other conservatives like Daily Signal correspondent Elizabeth Mitchell also criticized the comments of Makary about mifepristone.

“The abortion pill is not safe for the mother or the baby,” Mitchell also wrote on X. “The ER visitation rate for abortion complications appears to have increased since the FDA removed guardrails on the pill.”

Check out Abortions.news for more stories related to the murder of the unborn.

Watch the full episode of the “Health Ranger Report” with Mike Adams and Susan Swift as they discuss the dismantling of the abortion cartels.

This video is from the Health Ranger Report channel on Brighteon.com.

FDA commissioner stands firm on mifepristone access despite pressure from pro-life groups

Makary faces criticism from conservatives

More related stories:

RECENT NEWS & ARTICLES